BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32888145)

  • 1. Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population.
    Rogoża-Janiszewska E; Malińska K; Górski B; Scott RJ; Cybulski C; Kluźniak W; Lener M; Jakubowska A; Gronwald J; Huzarski T; Lubiński J; Dębniak T
    Breast Cancer; 2021 Jan; 28(1):226-235. PubMed ID: 32888145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
    BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
    Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
    Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
    Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
    Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
    J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
    Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
    Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
    Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent TP53 missense mutation in cancer patients of Arab descent.
    Zick A; Kadouri L; Cohen S; Frohlinger M; Hamburger T; Zvi N; Plaser M; Avital E; Breuier S; Elian F; Salah A; Goldberg Y; Peretz T
    Fam Cancer; 2017 Apr; 16(2):295-301. PubMed ID: 27866339
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
    Kwong A; Shin VY; Ho CYS; Au CH; Slavin TP; Weitzel JN; Chan TL; Ma ESK
    BMC Cancer; 2020 Nov; 20(1):1053. PubMed ID: 33138793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
    Aceto GM; Awadelkarim KD; Di Nicola M; Moscatello C; Pantalone MR; Verginelli F; Elwali NE; Mariani-Costantini R
    Breast Cancer Res Treat; 2019 Jun; 175(2):479-485. PubMed ID: 30796655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
    Melhem-Bertrandt A; Bojadzieva J; Ready KJ; Obeid E; Liu DD; Gutierrez-Barrera AM; Litton JK; Olopade OI; Hortobagyi GN; Strong LC; Arun BK
    Cancer; 2012 Feb; 118(4):908-13. PubMed ID: 21761402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of germline mutations in breast cancer: TP53.
    Schon K; Tischkowitz M
    Breast Cancer Res Treat; 2018 Jan; 167(2):417-423. PubMed ID: 29039119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
    BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Germline mutations of TP53 gene among Chinese families with high risk for breast cancer].
    Yang X; Hu Z; Wu J; Liu G; Di G; Chen C; Hou Y; Huang X; Liu Z; Shen Z; Shao Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):761-5. PubMed ID: 26663043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.